Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 491 word(s) 491 2020-12-15 07:46:55

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Zhou, V. CBFB Gene. Encyclopedia. Available online: https://encyclopedia.pub/entry/5079 (accessed on 02 March 2024).
Zhou V. CBFB Gene. Encyclopedia. Available at: https://encyclopedia.pub/entry/5079. Accessed March 02, 2024.
Zhou, Vicky. "CBFB Gene" Encyclopedia, https://encyclopedia.pub/entry/5079 (accessed March 02, 2024).
Zhou, V. (2020, December 24). CBFB Gene. In Encyclopedia. https://encyclopedia.pub/entry/5079
Zhou, Vicky. "CBFB Gene." Encyclopedia. Web. 24 December, 2020.
CBFB Gene
Edit

core-binding factor subunit beta

genes

1. Normal Function

The CBFB gene provides instructions for making a protein called core binding factor beta (CBFβ), which is one piece of a protein complex known as core binding factor (CBF). CBFβ attaches (binds) to one of three related RUNX proteins (RUNX1, RUNX2, or RUNX3) to form different versions of CBF. These protein complexes bind to specific regions of DNA and help turn on (activate) certain genes.

The presence of CBFβ helps the complex bind to DNA and protects the RUNX protein from being broken down. The function of CBF depends on which RUNX protein it includes. Once bound to DNA, the RUNX1 protein controls the activity of genes involved in the development of blood cells (hematopoiesis). The RUNX2 protein regulates genes important for bone cell development and formation of the skeleton. The RUNX3 protein primarily affects genes involved in the development of nerve cells.

2. Health Conditions Related to Genetic Changes

2. Core binding factor acute myeloid leukemia

Rearrangements of genetic material affecting the CBFB gene are involved in a form of blood cancer known as acute myeloid leukemia (AML). Because the genetic changes affect CBF, the condition is classified as core binding factor AML (CBF-AML). The most common of these rearrangements is an inversion of a region of chromosome 16 (written as inv(16)). An inversion involves breakage of the chromosome in two places; the resulting piece of DNA is reversed and reinserted into the chromosome. Less commonly, a rearrangement known as a translocation occurs between the two copies of chromosome 16 (written as t(16;16)). In this translocation, pieces of DNA from each copy of the chromosome break off and are interchanged. Both types of genetic rearrangement lead to the fusion of parts of two genes on chromosome 16, CBFB and MYH11. These rearrangements are associated with 5 to 8 percent of cases of AML in adults.

When these rearrangements occur in early blood cells, the function of the RUNX1 protein is particularly affected. The protein produced from the fusion gene, called CBFβ-MYH11, can still bind to RUNX1 to form CBF. However, the function of CBF is impaired. The presence of CBFβ-MYH11 may block binding of CBF to DNA, preventing RUNX1 from controlling gene activity. Alternatively, the MYH11 portion of the fusion protein may interact with other proteins that prevent RUNX1 from controlling gene activity. This change in gene activity blocks the maturation (differentiation) of blood cells and leads to the production of abnormal, immature white blood cells called myeloid blasts. While inv(16) and t(16;16) are important for leukemia development, one or more additional genetic changes are typically needed for the myeloid blasts to develop into cancerous leukemia cells.

3. Other Names for This Gene

  • CBF-beta
  • core-binding factor beta subunit
  • core-binding factor, beta subunit
  • PEA2-beta
  • PEBB_HUMAN
  • PEBP2-beta
  • PEBP2B
  • polyomavirus enhancer binding protein 2, beta subunit
  • polyomavirus enhancer-binding protein 2 beta subunit
  • SL3-3 enhancer factor 1 beta subunit
  • SL3-3 enhancer factor 1 subunit beta
  • SL3/AKV core-binding factor beta subunit

References

  1. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acutemyeloid leukemia. Am J Hematol. 2012 Mar;87(3):317-8. doi: 10.1002/ajh.22258.
  2. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia:current knowledge and future prospects. Int J Hematol. 2011 Aug;94(2):126-133.doi: 10.1007/s12185-011-0858-z.
  3. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization withPEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.EMBO J. 2001 Feb 15;20(4):723-33.
  4. Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by theinv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene. 2004 May 24;23(24):4297-307.Review.
  5. Yoshida CA, Furuichi T, Fujita T, Fukuyama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T. Core-binding factor beta interacts with Runx2 and isrequired for skeletal development. Nat Genet. 2002 Dec;32(4):633-8.
More
Information
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 247
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 24 Dec 2020
1000/1000